View the slides from AVAC Executive Director Mitchell Warren plenary presentation at SYNChronicity 2026.
Opportunities, Controversies & Cruel Ironies
What's New & Next in HIV Prevention
The Power of bNAbs: A new frontier in HIV cure research
In this video, from the Series of Jojo, viewers are introduced to broadly neutralizing antibodies (bNAbs) and how they might one day be used in finding a functional cure for HIV.
10 Minutes with JPIDS
Senior Program Manager of Cure Advocacy, Jessica Salzwedel, is featured on the Journal of Pediatric Infectious Disease Society podcast discussing a recent publication on the ethics of pediatric HIV cure research, “HIV Cure Research: Ethical and Real-World Practical Considerations for Pediatric and Adolescent Populations”. The podcast discusses work born out of the PAVE Collaboratory, the only HIV cure research consortium focused on perinatal HIV.
STIWatch Quarterly Newsletter
March 2026
As many global health fields reassess their reliance on US government funding for research and development, the STI field—already underfunded and reliant on alternate donors—now faces even greater uncertainty. In this newsletter, we share a new STI resource for advocates and highlight the top issues we’re monitoring as events continue to unfold.
AVAC Infographics for CROI 2026
Going to CROI? AVAC’s up-to-date infographics — on the research & development pipeline, prevention options, and the impact of US funding cuts — are available here for use in conference presentations. We constantly update these graphics, so check back for updates. The latest version of the deck will be available here.
AVAC Year in Review 2025
2025 underscored the vital role that AVAC plays in the global health ecosystem, and why our work and our partnerships have never been more essential.
This report highlights AVAC’s role as a trusted voice, a translator of science and catalyst for action and advocacy. It reflects an organization ready for the future: supporting African leadership, strengthening bridges from R&D to delivery and preparing for a new chapter as we move forward into our fourth decade as an organization. Read the PDF below or view as a webpage.
An Overview of Lenacapavir for PrEP Trials
Change in PrEP Initiations from 2024 to 2025 in Five Countries
Between the period January-September 2024 to January-September 2025, PrEP initiations fell between 13% and 66% in selected high-volume PrEP countries where ministries of health (MoH) were able to provide data. Among the five countries depicted, four saw significant decline in PrEP uptake. All four relied on PEPFAR PrEP programs and were disrupted by stop work orders (SWO).
Dapivirine Vaginal Ring Regulatory Approval
Regulatory approvals, pending decisions, and appeals as of January 2026. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.
Cabotegravir Regulatory Approval
Regulatory approvals and those pending for cabotegravir as of January 2026. For product approvals, volumes, implementation, and price comparisons of long-acting PrEP, visit our dashboard on PrEPWatch.org.